Baxter International, Inc.

742 articles with Baxter International, Inc.

• Baxter Unveils New Products at the ASMBS – Obesity Week Meeting to Help Surgeons Overcome Challenges During Bariatric Surgery

  11/14/2018

  Peri-Strips Circular with Secure Grip technology provides several advantages in application and patient outcomes

• Baxter Declares Quarterly Dividend in 2019 and Announces Expanded Share Repurchase Authorization

  11/13/2018

  The indicated annual dividend rate is $0.76 per share of common stock.

• Baxter Highlights Data at ISPOR Europe 2018 on Clinical and Economic Benefits When Addressing Malnutrition, Intraoperative Bleeding

  11/13/2018

  Baxter International Inc. (NYSE:BAX), a leading global medical products company, is presenting four health economics and outcomes research (HEOR) analyses this week at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2018 meeting.

• Baxter Introduces New Tisseel Prima Syringe at 2018 American Association of Gynecologic Laparoscopists Meeting

  11/12/2018

  Next-generation syringe provides physicians with enhanced speed, precision and control during surgery

• Baxter to Present at Citi’s 2018 Global Healthcare Conference

  11/6/2018

  Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at Citi’s 2018 Global Healthcare Conference on Thursday, December 6, 2018, in New York. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 11:45 a.m. EST.

• Baxter Reports Third-Quarter 2018 Results and Updates Financial Outlook for Full-Year 2018

  10/31/2018

  Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the third quarter of 2018 and updated its full-year 2018 financial outlook.

• Baxter Highlights Clinical Data at ASN: Kidney Week Showing How New Technologies Are Advancing Dialysis Care across Modalities

  10/29/2018

  Thirteen studies presented on HDx therapy enabled by Theranova adding to significantly growing global clinical evidence

• Baxter Receives CE Mark for PrisMax, the Next-Generation System for Continuous Renal Replacement and Organ Support Therapies

  10/29/2018

  ​Innovative features inspired by clinician feedback make delivering therapy simpler and more efficient

• Baxter Announces U.S. Regulatory Filing for PrisMax Acute Care System and Presentation of 15 Abstracts to Start ASN: Kidney Week 2018

  10/25/2018

  PrisMax incorporates advanced technology for continuous renal replacement therapy (CRRT) designed to increase accuracy and performance for critically ill patients

• Baxter to Showcase Critical Care Innovation at the 2018 European Society of Intensive Care Medicine Congress

  10/19/2018

  Product innovations with recent approvals across Baxter’s Acute Therapies, Clinical Nutrition and Medication Delivery businesses to be featured

• Baxter and ASPEN Launch “SmartPN” Tools to Reinforce Appropriate Use of Parenteral Nutrition

  10/10/2018

  Today the American Society for Parenteral and Enteral Nutrition (ASPEN), an organization which drives the science and practice of clinical nutrition, and Baxter International Inc.

• Baxter and Mayo Clinic Announce Collaboration to Establish Renal Care Center of Excellence in the U.S.

  10/2/2018

  Collaboration combines the clinical expertise of Mayo Clinic and Baxter Renal Care Services

• Baxter Collaborates with University of Southern California Center for Body Computing to Advance Digital Health Solutions

  9/28/2018

  Focuses on digital health initiatives intended to improve health outcomes and drive increased efficiency

• Baxter Announces U.S. FDA Clearance of ALTAPORE Bioactive Bone Graft in Posterolateral Spine Surgery

  9/26/2018

  Specially designed to enhance and accelerate bone growth with proprietary silicate-substituted technology and optimized micro and macro porosity

• Baxter Recognized as One of Working Mother’s 2018 ‘100 Best Companies’

  9/25/2018

  Baxter International Inc. today announced that it has been named to Working Mother magazine’s 2018 ‘100 Best Companies’ list.

• Baxter to Host Third Quarter 2018 Financial Results Conference Call for Investors

  9/20/2018

  Baxter International Inc. will host a conference call to discuss its third quarter 2018 financial results on Wednesday, October 31, 2018, at 7:30 a.m. Central Time.

• Polyganics Strengthens Global Distribution Network with Appointment of Synovis MCA as US-wide Distributor of NEUROCAP®

  9/10/2018

  Polyganics today announced that it has signed an agreement with Synovis Micro Companies Alliance Inc. to be the exclusive distributor of its nerve capping device, NEUROCAP®, in the US.

• Baxter Announces U.S. FDA Clearance of New Bone Graft Substitute, Actifuse Flow

  9/6/2018

  Ready-to-use synthetic bone graft substitute designed for ease of use and fast application

• Baxter Announces CE Mark and Regulatory Approval of New Evo IQ Infusion System for the United Kingdom, Ireland, Australia and New Zealand

  8/1/2018

  Delivers a state-of-the-art system with proven Dose IQ Safety Software to help elevate the standard of patient safety

• Baxter Reports Second-Quarter 2018 Results and Increases Earnings Outlook for Full-Year 2018

  7/26/2018

  Second-quarter revenue of $2.8 billion increased 9 percent on a reported basis and 4 percent on an operational basis